Immunohistochemical study of cyclooxygenase-2 in skin tumors
Mehdi Amirnia1, Arash Babaie-Ghazani, Ashraf Fakhrjou
1Department of Dermatology, Sina Hospital, Tabriz University of Medical Sciences , Tabriz , Iran.
Introduction:
Anti-cancerous effects of cyclooxygenase-2 (COX-2) inhibitors have been reported in different cancers. High expression of COX-2 has been demonstrated in various neoplasms such as colorectal, gastric, esophageal, breast, non-small cell lung cancers, and pre-neoplastic lesions such as colorectal adenomas and Barrett's esophagus.
Goal:
The purpose of this study was to investigate percentage of positive COX-2 expression in skin tumors, including pre-malignant and malignant tumors.
Methods:
This is an analytic cross-sectional study that includes 62 skin tumor samples, among which 49 samples were malignant and 13 were pre-malignant. After study for determination of pathologic kind of tumors, samples underwent immunohistochemical study for COX-2 expression. The DakoCytomation EnVision+System-HRP is a two-step extremely sensitive IHC staining technique which we used in this study.
Results:
Among the skin tumors, a considerable number of COX-2 expression were found in squamous cell carcinomas (SCC) (16 of 17; 94%), basal cell carcinomas (BCC) (28 of 32; 87.5%), Bowen's disease (BD) (8 of 9; 89%), and actinic keratosis (AK) (4 of 4; 100%).
Conclusion:
COX-2 expression was positive in skin tumors including malignant and pre-malignant skin lesions. This study strongly suggests that COX-2 can be one of the molecular targets in treating various skin tumors.
Insights
Cyclooxygenase-2 (COX-2) is highly expressed in various skin tumors, including pre-malignant and malignant types. This suggests COX-2 as a potential therapeutic target for skin cancer treatment.
Area of Science:
- Oncology
- Dermatology
- Molecular Biology
Background:
- Cyclooxygenase-2 (COX-2) inhibitors show anti-cancer effects in various neoplasms.
- High COX-2 expression is noted in colorectal, gastric, esophageal, breast, and lung cancers, as well as pre-neoplastic lesions.
- COX-2's role in skin tumorigenesis is an area of active investigation.
Purpose of the Study:
- To determine the percentage of positive COX-2 expression in a cohort of skin tumors.
- To analyze COX-2 expression in both pre-malignant and malignant skin lesions.
Main Methods:
- An analytic cross-sectional study was conducted on 62 skin tumor samples (49 malignant, 13 pre-malignant).
- Pathologic classification of tumors was performed.
- Immunohistochemical staining for COX-2 expression was utilized using the DakoCytomation EnVision+System-HRP technique.
Main Results:
- High COX-2 expression was observed in squamous cell carcinomas (94%) and basal cell carcinomas (87.5%).
- Bowen's disease (89%) and actinic keratosis (100%) also showed considerable COX-2 expression.
- Positive COX-2 expression was prevalent across malignant and pre-malignant skin lesions.
Conclusions:
- COX-2 is frequently expressed in both pre-malignant and malignant skin tumors.
- These findings highlight COX-2 as a promising molecular target for the treatment of diverse skin cancers.
- Further research into COX-2 targeted therapies for skin neoplasms is warranted.
